

# Michael D Tarantino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2427795/publications.pdf>

Version: 2024-02-01

27  
papers

3,144  
citations

687220

13  
h-index

552653

26  
g-index

27  
all docs

27  
docs citations

27  
times ranked

2457  
citing authors

#	ARTICLE	IF	CITATIONS
1	International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i> , 2010, 115, 168-186.	0.6	1,802
2	Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. <i>Lancet</i> , The, 2008, 371, 395-403.	6.3	784
3	Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet</i> , The, 2016, 388, 45-54.	6.3	116
4	Single dose of anti-D immune globulin at 75 $\hat{1}$ / <sub>4</sub> g/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. <i>Journal of Pediatrics</i> , 2006, 148, 489-494.	0.9	104
5	Factor VIII replacement is still the standard of care in haemophilia A. <i>Blood Transfusion</i> , 2019, 17, 479-486.	0.3	53
6	Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia. <i>Journal of Clinical Medicine</i> , 2021, 10, 2471.	1.0	47
7	Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. <i>Journal of Medical Economics</i> , 2020, 23, 184-192.	1.0	29
8	Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia. <i>Haematologica</i> , 2019, 104, 2283-2291.	1.7	27
9	The Child With Immune Thrombocytopenic Purpura: Is Pharmacotherapy or Watchful Waiting the Best Initial Management?. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 146-151.	0.3	22
10	Romiplostim as a treatment for immune thrombocytopenia: a review. <i>Journal of Blood Medicine</i> , 2015, 6, 37.	0.7	22
11	Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity. <i>Acta Haematologica</i> , 2015, 134, 215-228.	0.7	22
12	Risk factors associated with intraventricular hemorrhage in extremely premature neonates. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 25-29.	0.5	19
13	Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. <i>Platelets</i> , 2016, 27, 472-478.	1.1	14
14	Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag. <i>Platelets</i> , 2015, 26, 93-96.	1.1	13
15	Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag. <i>Platelets</i> , 2014, 25, 55-61.	1.1	11
16	The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States. <i>Platelets</i> , 2020, 31, 307-314.	1.1	10
17	Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 284-296.	0.5	9
18	Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. <i>Blood Reviews</i> , 2021, 49, 100811.	2.8	9

#	ARTICLE	IF	CITATIONS
19	Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28630.	0.8	6
20	Natural history study of factor IX deficiency with focus on treatment and complications (Bâ€Natural). <i>Haemophilia</i> , 2021, 27, 49-59.	1.0	6
21	Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency. <i>Haemophilia</i> , 2021, 27, 531-543.	1.0	5
22	Quality of life in a large multinational haemophilia B cohort (The Bâ€Natural study) â€“ Unmet needs remain. <i>Haemophilia</i> , 2022, 28, 453-461.	1.0	5
23	Hemophilia Management via Data Collection and Reporting: Initial Findings from the Comprehensive Care Sustainability Collaborative. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 51-56.	0.5	3
24	Immune Thrombocytopenia in US Clinical Practice: Incidence and Healthcare Utilization/Expenditures in the First 12 Months Following Diagnosis. <i>Blood</i> , 2018, 132, 2239-2239.	0.6	3
25	Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry. <i>Blood Advances</i> , 2021, 5, 4969-4979.	2.5	2
26	Characterization of Laboratory Coagulation Parameters and Risk Factors for Intraventricular Hemorrhage in Extremely Premature Neonates. <i>Journal of Thrombosis and Haemostasis</i> , 2022, , .	1.9	1
27	Central venous access device catheter fragmentation at time of removal in four patients with haemophilia A. <i>Haemophilia</i> , 2019, 25, e185-e188.	1.0	0